Identification of differentially expressed microRNAs in human hepatocellular adenoma associated with type I glycogen storage disease: A potential utility as biomarkers

Journal of Gastroenterology

Volumn 49, Issue 8, 2014, Pages 1274-1284

  Chiu, Li Ya ^a   Kishnani, Priya S ^b   Chuang, Tzu Po ^c,d   Tang, Cheng Yang ^a   Liu, Cheng Yuan ^e   Bali, Deeksha ^b   Koeberl, Dwight ^b   Austin, Stephanie ^b   Boyette, Keri ^b   Weinstein, David A ^f   Murphy, Elaine ^g   Yao, Adam ^a,c   Chen, Yuan Tsong ^b,c   Li, Ling Hui ^a,c  

^a ACADEMIA SINICA   (Taiwan)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e Taiwan Tech   (Taiwan)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Glycogen storage disease; Hepatocellular adenoma; Hepatocellular carcinoma; miR 130b; miRNA

Indexed keywords

MICRORNA; MIRN130 MICRORNA, HUMAN; TUMOR MARKER;

ADENOMA, LIVER CELL; CASE CONTROL STUDY; COMPLICATION; DOWN REGULATION; GENETICS; GLYCOGEN STORAGE DISEASE TYPE 1; HUMAN; LIVER NEOPLASMS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; UPREGULATION;

ADENOMA, LIVER CELL; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DOWN-REGULATION; GLYCOGEN STORAGE DISEASE TYPE I; HUMANS; LIVER NEOPLASMS; MICRORNAS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84905654192     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0890-2     Document Type: Article

References (49)

1. Lei KJ, Shelly LL, Pan CJ, Sidbury JB, Chou JY. Mutations in the glucose-6-phosphatase gene that cause glycogen storage disease type 1a. Science. 1993;262:580-3. (Pubitemid 23350674)
2. Hiraiwa H, Pan C-J, Lin B, Moses SW, Chou JY. Inactivation of the glucose 6-phosphate transporter causes glycogen storage disease type 1b. J Biol Chem. 1999;274:5532-6. (Pubitemid 29109201)
3. Bali DS, Chen YT, Goldstein JL. Glycogen storage disease type I. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviews. Seattle; 1993.
4. Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr. 1993;152(Suppl 1):S63-70. (Pubitemid 23134782)
5. Di Rocco M, Calevo MG, Taro M, Melis D, Allegri AE, Parenti G. Hepatocellular adenoma and metabolic balance in patients with type Ia glycogen storage disease. Mol Genet Metab. 2008;93:398-402.
6. Smit GP, Fernandes J, Leonard JV, Matthews EE, Moses SW, Odievre M, et al. The long-term outcome of patients with glycogen storage diseases. J Inherit Metab Dis. 1990;13:411-8. (Pubitemid 20374447)
7. Lee P, Mather S, Owens C, Leonard J, Dicks-Mireaux C. Hepatic ultrasound findings in the glycogen storage diseases. Br J Radiol. 1994;67:1062-6.
8. Talente GM, Coleman RA, Alter C, Baker L, Brown BI, Cannon RA, et al. Glycogen storage disease in adults. Ann Intern Med. 1994;120:218-26. (Pubitemid 24038807)
9. Labrune P, Trioche P, Duvaltier I, Chevalier P, Odievre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr. 1997;24:276-9. (Pubitemid 27199615)
10. Weinstein DA, Wolfsdorf JI. Effect of continuous glucose therapy with uncooked cornstarch on the long-term clinical course of type 1a glycogen storage disease. Eur J Pediatr. 2002;161(Suppl 1):S35-9.
11. Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr. 2002;161(Suppl 1):S20-34.
12. Reddy SK, Kishnani PS, Sullivan JA, Koeberl DD, Desai DM, Skinner MA, et al. Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia. J Hepatol. 2007;47:658-63. (Pubitemid 47503424)
13. Wang DQ, Carreras CT, Fiske LM, Austin S, Boree D, Kishnani PS, et al. Characterization and pathogenesis of anemia in glycogen storage disease type Ia and Ib. Genet Med. 2012;14:795-9.
14. Cho SW, Marsh JW, Steel J, Holloway SE, Heckman JT, Ochoa ER, et al. Surgical management of hepatocellular adenoma: take it or leave it? Ann Surg Oncol. 2008;15:2795-803.
15. Lin H, van den Esschert J, Liu C, van Gulik TM. Systematic review of hepatocellular adenoma in China and other regions. J Gastroenterol Hepatol. 2011;26:28-35.
16. Farges O, Ferreira N, Dokmak S, Belghiti J, Bedossa P, Paradis V. Changing trends in malignant transformation of hepatocellular adenoma. Gut. 2011;60:85-9.
17. Limmer J, Fleig WE, Leupold D, Bittner R, Ditschuneit H, Beger HG. Hepatocellular carcinoma in type I glycogen storage disease. Hepatology. 1988;8:531-7.
18. Kudo M. Hepatocellular adenoma in type Ia glycogen storage disease. J Gastroenterol. 2001;36:65-6. (Pubitemid 32140693)
19. Franco LM, Krishnamurthy V, Bali D, Weinstein DA, Arn P, Clary B, et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis. 2005;28:153-62. (Pubitemid 40723883)
20. Kishnani PS, Chuang TP, Bali D, Koeberl D, Austin S, Weinstein DA, et al. Chromosomal and genetic alterations in human hepatocellular adenomas associated with type Ia glycogen storage disease. Hum Mol Genet. 2009;18:4781-90.
21. Calderaro J, Labrune P, Morcrette G, Rebouissou S, Franco D, Prevot S, et al. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J Hepatol. 2012;58:350-7.
22. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-97.
23. Li W, Xie L, He X, Li J, Tu K, Wei L, et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer. 2008;123:1616-22.
24. Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res. 2008;14:419-27. (Pubitemid 351226109)
25. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303:83-6. (Pubitemid 38055775)
26. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122:6-7. (Pubitemid 40977933)
27. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011;39:D152-7.
28. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259-69.
29. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med. 2006;12:580-7. (Pubitemid 44780201)
30. Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 2008;47:1955-63. (Pubitemid 351952843)
31. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006;5:29.
32. Wu W, Sun M, Zou GM, Chen J. MicroRNA and cancer: current status and prospective. Int J Cancer. 2007;120:953-60. (Pubitemid 46214293)
33. Liu AM, Yao TJ, Wang W, Wong KF, Lee NP, Fan ST, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open. 2012;2:e000825.
34. Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol. 2012;56:167-75.
35. Chen CF, Hsu EC, Lin KT, Tu PH, Chang HW, Lin CH, et al. Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma. Hepatology. 2010;52:1690-701.
36. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA. 2010;107:264-9.
37. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513-8.
38. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2006;25:2537-45.
39. Shen Q, Cicinnati VR, Zhang X, Iacob S, Weber F, Sotiropoulos GC, et al. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer. 2010;9:227.
40. Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, et al. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem. 2008;283:13205-15.
41. Weng Z, Wang D, Zhao W, Song M, You F, Yang L, et al. microRNA-450a targets DNA methyltransferase 3a in hepatocellular carcinoma. Exp Ther Med. 2011;2:951-5.
42. Gao P, Wong CC, Tung EK, Lee JM, Wong CM, Ng IO. Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol. 2011;54:1177-84.
43. Li Q, Wang G, Shan JL, Yang ZX, Wang HZ, Feng J, et al. MicroRNA-224 is upregulated in HepG2 cells and involved in cellular migration and invasion. J Gastroenterol Hepatol. 2010;25:164-71.
44. Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant BC, Slagle BL, et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol. 2008;173:856-64.
45. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell. 2010;7:694-707.
46. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647-58. (Pubitemid 47187346)
47. Shih TC, Tien YJ, Wen CJ, Yeh TS, Yu MC, Huang CH, et al. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J Hepatol. 2012;57:584-91.
48. Wang C, Song B, Song W, Liu J, Sun A, Wu D, et al. Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1alpha in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients. J Gastroenterol Hepatol. 2011;26:1630-7.
49. Wang Y, Toh HC, Chow P, Chung AY, Meyers DJ, Cole PA, et al. MicroRNA-224 is upregulated in hepatocellular carcinoma through epigenetic mechanisms. FASEB J. 2012;26:3032-41.